InflaRx Announces Decision to Enter Phase III Development of IFX‑1 in Severe COVID-19 Induced Pneumonia

Tag: Antibodies

Prof. Niels C. Riedemann, CEO of InflaRx in the laboratory

InflaRx Announces Decision to Enter Phase III Development of IFX‑1 in Severe COVID-19 Induced Pneumonia

The bm|t Investee partner InflaRx plans to continue the development through a double-blind, randomised, placebo-controlled Phase III study.

July, 31 2020

InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology

InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX‑1 in patients with severe COVID-19 pneumonia in the Netherlands InflaRx received

April, 1 2020